Augustine Therapeutics, a Leuven, Belgium-based biotechnology firm centered on creating new therapies by means of the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, raised EUR 77.7M in Collection A funding.
The spherical was co-led by Novo Holdings and Jeito Capital with participation from Asabys Companions, who led an preliminary EUR 17.5M closing in 2024, Eli Lilly and Firm, AdBio companions, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Analysis Basis and Newton Biocapital.
The corporate intends to make use of the funds to advance its lead candidate, AGT-100216, by means of a Part I/II proof-of-concept medical trial in CMT.
Led by CEO Gerhard Koenig, Augustine Therapeutics is a biotechnology firm centered on the therapy of neuromuscular, neurodegenerative and cardio-metabolic ailments by means of its method to selectively inhibit HDAC6. Its lead program, AGT-100216, is the primary selective HDAC6 inhibitor for long-term therapy of Charcot-Marie-Tooth (CMT) illness. With its non-hydroxamate, non-hydrazide producing chemotype, the HDAC6 method is selective, avoids the constraints of different chemotypes, and constructed for power ailments.
It was based on the analysis of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium.
FinSMEs
24/03/2025
